World has ‘never experienced’ soaring refining margins like this, TotalEnergies CEO tells CNBC
TotalEnergies CEO Patrick Pouyanné on the Iran war, the $1 billion deal with the White House, investment in the U.S., and more.
The charts to watch in tech, gold and emerging market stocks as volatility persists
Todd Gordon also talks about the portfolio changes he’s made to navigate this environment.
Dimon warns on AI job losses, calls for government-business incentives
The potential AI-related disruption of the job market is a critical issue in Washington, with lawmakers trying to curb the amount of displacement.
Micron stock sinks for a fourth straight day despite dominant earnings report
Micron’s revenue almost tripled in the last quarter, but the memory company’s stock has sunk about 15% since it reported earnings on Wednesday.
Arm releases first in-house chip, with Meta as debut customer
Arm is making its first CPU, pivoting from only licensing its architecture to giants like Apple, Nvidia, Amazon and Google. CNBC got an exclusive first look.
Strait of Hormuz tanker traffic won’t return to normal for months, Kalshi bettors predict
Prediction market bettors aren’t confident that the vital Middle Eastern oil passageway will reopen anytime soon.
Iran war has altered the global natural gas market. Goldman says these 3 stocks will benefit
Liquid natural gas plays are set to win thanks to constrained supply, even if demand eases due to higher prices.
Jamie Dimon says Iran war makes Middle East peace prospects better in the long term
JPMorgan Chase CEO Jamie Dimon issued an optimistic viewpoint on Middle East peace, weeks into the war with Iran.
Circle posts worst day on record as proposed law could limit stablecoin yield
Earning yield, usually in the form of rewards, on stablecoins like Circle’s USDC and others is key incentive for users to hold the coins.
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
Analysts see the biotech company as a prime takeover target and several pharma giants have been rumored as potential buyers.
